Development of chimeric antigen receptor-modified T cells for the treatment of esophageal cancer.

CONCLUSIONS: An effective HER2 CAR targeting ESCC was developed successfully. The HER2.CAR-T cell showed promising immunotherapeutic potential for the treatment of HER2-positive esophageal cancer.
PMID: 32988314 [PubMed - as supplied by publisher]

Source: Tumori - October 1, 2020 Category: Cancer & Oncology Tags: Tumori Source Type: research